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onary artery smooth muscle cells (HCASMC). respectively. Methods: HACM were iso- 
lated from recipients’ hearts after heart transplantation and characterized by positive 
staining for troponin-I and cardiotin. The cells were negative for two fibroblast-specific 
antibodies as well as for desmin and vWF Indicating the absence of Lbroblasts. smooth 
muscle cells and endothelial cells. HCASMC were isolated from recipients’ coronary 
arteries using the explant-technique and stained positive for alpha-smooth muscle actin. 
Such characterized cells were treated with PGEl and effects on VEGF-A expression 
were studied using an ELISA and RT-PCR. Results When HACM or HCASMC were 
treated wrth PGEI, a significant up to threefold increase in VEGF-A productIon could be 
observed. These results could be confirmed on the level of specific mRNA expression as 
determined by RT-PCR. The effect of PGEI on VEGF-A expression could be reversed 
by periussis toxin. Conclusion: We conclude from our data that PGEI-induced expres- 
sion of VEGF-A in cardiac myocytes and smooth muscle cells might contribute to its ben- 
eflclal effects seen in patients with ischaemlc heart disease. It should, however, be 
mentIoned that increased production of VEGF in smooth muscle cells could potentially 
also Induce anglogenesIs within the atherosclerotic plaque and thereby could contribute 
to plaque destabilization. 
1054-l 43 Different Cell Death Rates Determine Growth of 
Vascular Smooth Muscle Cells From Human 
Aortocoronary Bypass Vessels: Implications for 
Patency of Radial Artery Grafts 
Karln Frischknecht, Helen Greutert. Thierry P. Carrel, Felix C. Tanner, University 
Hospital Bern, Bern, Switzerland 
Long-term patency of aortocoronary bypass grafts IS determined by vascular smooth 
muscle cell (VSMC) proliferation leading to neointlma formation. Radial artery (RA) 
patency rates ?&em to be in between those from mammary artery (MA) and saphenous 
vein (SV). We therefore examined whether and. If so, why proliferation of VSMC from 
these bypass vessels differs accordingly. After 6 days of serum stimulation, RA-VSMC 
number (51’520+7’536) was lower than SV (69’750+11’586), but higher than MA 
(26’365&324) (SV vs. MA: p<O.Ol/ SV or MA vs. RA: p=n.s.: n=4). In contrast. RA- 
VSMC exhIbIted only minimal proliferation to PDGF-BE, (15’493i2’116), which was com- 
parable to MA (15’446+2’768; MA vs RA: p=n.s.) and differed from SV (33’094&3’028; 
SV vs. RA or MA: pcO.01; n=4). Analogous results were obtained by SH-thymldme incor- 
poration (n=4). As determmed by FACS analysis, PDGF receptorp expression was simi- 
lar (p=n.s.; n=5), whereas PDGF receptor p expression was higher in RA as compared to 
MA or SV (RA vs. MA or SV: ~~0.05; MA vs. SV: p=n.s.; n=5). Western blotting con- 
firmed these findings. Propidium iodide incorporation after PDGF stimulation showed 
identical cell cycle distribution in VSMC from all three vessels. Similarly, Western blotting 
for cell cycle proteins after PDGF treatment revealed identical expression: the cyclin- 
dependent kinase inhibitor (CKI) p27 was downregulated, the CKI ~21 was slightly 
induced, while the CKI ~57, cyclin-dependent kinase 2 (cdk2) and cyclm E did not show 
any change. CdkP klnase assay confirmed that Gl progression was identical in VSMC 
from all three vessels. While neither the visual aspect nor trypane blue staining were dif- 
ferent. LDH release was higher in VSMC from MA as compared to RA or SV (SV vs. MA: 
pcO.05; RA vs. MA or SV: p=n.s.. n=5). Thus, cell cycle progression is identical in VSMC 
from human bypass vessels, while different cell death rates determine growth, suggest- 
ing that VSMC death rather than proliferation may account for the different patency rates 
of bypass grafts. The weak effect of PDGF in RA as compared to SV encourages the 
clinical use of RA grafts 
1054-144 Activated Protein C inhibits the Release of 
Proinflammatory Cytokines and Chemokines From the 
Monocytic Cell Line THP-1 
Mariina Brueckmann, Hans Martin Weiler. An@? Marx, Volker Liebe, Siegfried Lang, 
Martin Borggrefe, Guenter Huhle, Karl K. Haase, University Hospital of Mannheim, 
Mannhelm, Germany 
Background: It has been suggested that the activated pro&In C (APC) pathway serves 
as a common link between coagulation and Inflammation. This has been further sup- 
ported by reports showing that APC could inhibit or induce cytokine production in endot- 
helial cells. In addition to endothelial cells, monocyies are also important in the 
inflammatory response. In order to determine what effect APC may have on cytokine and 
chemokme production in monocytes, experiments were conducted using the monocytic 
cell line THP-1. We Investigated the effect of human APC on the monocytic release of the 
proinflammatory cytokines macrophage inflammatory protein-l-alpha (MIP l-alpha) and 
tumor necrosis factor-alpha (TNF-alpha) as well as the effect of APC on the release of 
the chemokine monocyte chemoattractant protein-l (MCP-1). All of these mediators may 
be important for the Interaction of monoytes at the endothelium during initiation and pro- 
gression of atherosclerosis. Methods and Res.uks: We established a monocyiic cell 
model of inflammation by the addition of llpopolysaccharlde (LPS from E.coli 026:86; O.l- 
1 W/ml) and examined the effect of APC on cytoklnelchemokine release. As a further 
extension of the effect of APC on cytokines, we found that human APC (2.5.lO~g/ml) 
inhiblted LPS-Induced release of MIP-l-alpha and MCP-1 from THP-1 cells, as mea- 
sured by an Enzyme-llnked immunosorbent assay at 6 up to 24 h. Furthermore APC 
inhibited the LPS-induced r&se of TNF-alpha, time- and dose-dependently.Conclu- 
sions: The ablkty of APC to Inhibit the release of the proinflammatory cytokines MIP-I- 
alpha and TNF-alpha and of the chemokine MCP-1 provides further evidence that APC 
may modulate initlatlon and progression of atherosclerotic lessons through the control of 
cytoklne and chemokine release from monocytes. 
1054- 145 The Coexpression of the Migration Inhibiting Factor l- 
Alpha With CD401 in Human Atherosclerotic Plaques Is 
Associated With Advanced Plaque Stages and Extent of 
lntraplaque Inflammation 
Alexander Schmeisser, Thomas Illmer, Christiane Graffy, Herriberl Loesel-Sadee, 
Dittmar Boeckler. Dittmar Menschikowski. Gerhard Ehninaer. Christoph Garlichs. Werner 
G. Daniel, Ruth H. Strasser, Technical University of Dresden, Dresden, Germany, 
University Erlangen-Nuernberg. Erlangen, Germany 
Background: MIF is a hormone and cytokine with pivotal importance in Inflammatory 
and immune responses. Little is known about the role of MIF in atherosclerotic plaque 
progression and inflammation. 
Methods: Carotid endartherectomy and vessel samples (n=46) were collected from 36 
patients and 4 young accident victim controls and histologtcal classified by Stary: minimal 
plaques (MP) were defined as Stary: O-ill and advanced plaques (AP) as Stary: IV-VIII. 
The immunhistochemlcal detectloo of MIF and CD401 in macrophages (Ma), microvascu- 
lar endothelial cells (MEC), vascular smooth muscle cells (VSMC) and T-lymphocytes 
(TL) was peiiomed. The relative extent of MIF expression was graded on scales of d0 to 
d3 in terms of specific staining intensity. In addition, the number intraplaque microvessels 
and inflammatory foci (z-10 CD45-positive mononuclear cells (MNC)/field) were counted. 
In vitro, the monocyte cell line THP-I was stimulated with a CD4OI-fusion protein 
(lmicroglml), lmglmicrol LPS or with heat denaturated CD401. 
Results: APs (n=36) shows sign. (p<O.Oi) more intimal MNC and intraplaque mlcroves- 
sels than MPs from patients/controls @IO), and higher MIF expressing intensltiy by MA/ 
TL and MVEC. Strong MIF staining (d2/d3) was detected in Ma’TL in 70% and MEC in 
80% of AP, and only in 10% and 0% of MP, respectively. Strong MIF staining was colo- 
calized with CD401 expresslo” in foci with Ma/TL stainmg. VSMC stained only weak or no 
for MIF. CD401 upregulated THP-1 MIF expression after 12h (mRNA) and 48h (protein) 
sign. (p-zO.01) and comparable to TNF-alpha in vitro. 
Conclusion: The results reveal a marked upregulatlon of migration inhibitory factor l-a 
in close correlation to macrophagefl-cell infiltratlon and intraplaque mlcrovessel extent in 
advanced plaques. Additionally, the coexpression with CD401 suggests a pivotal role of 
MIF in the inflammatory process and intimal neoangiogenesis of atherosclerotic plaques. 
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1055-117 Hammerhead Ribozymes Directed Against Cyclin E and 
E2Fl as Tools to Prevent In-Stent Restenosis 
ChrIstIan Herdeq, Martm Oberhoff, Stephen Schroeder, Anne Kuhn, Remhard Kandolf, 
Ludger Seipel, Gabriele Grassi, University of Tuebingen, Tuebingen, Germany 
In-stent-restenosis is associated with prolonged cellular proliferation in stented arteries. 
We explored the possibility to specifically inhibit vascular smooth muscle cell (VSMC) 
proliferation via hammerhead ribozymes. Two nbozymes. targeted against cyclin E and 
EZFl mRNAs. were used. As these two genes co-operate to promote the transition from 
Gi to S phase of the cell cycle, they represent ideal targets lo arrest cells in Gl phase 
thus blocking proliferation. 
Methods: Phosphorothioare-modified ribozymes complexed with llposomes were admin- 
istered to human VSMC. Cell proliferation and distribution throughout the phases of the 
cell cycle were analyzed by a double DNA staining procedure. The antlprolifeatiive effect 
of the specific ribozymes were evaluated in comparison to scrambled binding arm 
ribozymes (RzScr) liposomes alone and non-treated cells. Different ribozyme concentra- 
tions and times after transfection were tested. In addition, the effect of a combined 
administration of the two ribozymes was evaluated. Finally, a comparison between the 
efficacy of ribozymes and the corresponding antisense oligonucleotides (ODNs) was per- 
formed. 
Results: Two days after transfection, each of the two specific rlbozymes showed a dose- 
dependent Inhibition of proliferation in comparison to non-treated, liposome-treated and 
RzScr treated cells. Ribozyme effect peaked at 420 nM. reducing cell growth down to 34 
% of non treated cells. At the Same final concentration (420 nM), a combined admmistra- 
tion of the two ribozymes (210 nM each) resulted I” an even more pronounced proltfera- 
tion inhibition (25 % of non treated cells). Time course experiments showed that 
ribozyme aCtiVlty persists for at least four days following transfection. In addition, 
ribozymes were more effective than the respective antisense ODNs. Finally, we proved 
that growth Inhibition was due to an increase in Gl phase cells, paralleled by the con- 
comitant decrease in S phase cells. 
Conclusion: Ribozymes against cyclin E and E2Fl reduced VSMC proliferation up lo four 
days by arresting cells in Gl phase. The dramatic and specific decrease in cell growth 
provides the basis for the development of a ribozyme therapy for m-stem restenosis 
